Families Of Spinal Muscular Atrophy Announces Latest Developments On Three SMA Drug Discovery Programs
Families of Spinal Muscular Atrophy has just released details of the latest developments for the Families of SMA funded therapeutic pipeline. Families of SMA is currently funding three distinct drug discovery programs: 1) Quinazolines to boost gene expression; 2) Tetracyclines at Paratek Pharmaceuticals to correct gene splicing; and 3) Motor neuron replacement program at California Stem Cell and UCI.
More: continued here
Filed under: Muscular Dystrophy on June 25th, 2009
You must be logged in to post a comment.